VAMP associated protein B and CGenealiases: ALS8 · VAMP-B · VAP-B
Q-omics provides the consensus-scored VAPB profile across patient tissues and cancer cell-line models. VAPB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VAPB is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, VAPB protein abundance shows 27,054 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where VAPB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VAPB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VAPB survival associations across molecular data types. VAPB RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VAPB RNA expression–survival associations across cancer types. High VAPB expression shows unfavorable associations in UVM, CESC, LIHC, MESO and BLCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VAPB RNA expression.
This table summarizes VAPB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for VAPB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VAPB shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, LIHC and COAD. The THCA box plot shows higher VAPB RNA expression in normal versus tumor tissue (log2 FC = −1.587, t-test p < 0.001).
This table shows molecular features associated with VAPB in patient tissues and cancer cell lines. In patient samples, VAPB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VAPB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
